Axovant Sciences Ltd. has terminated its $187.5 million license and collaboration agreement with Benitec Biopharma Ltd., a Sydney-based gene therapy company, regarding AXO-AAV-OPMD (formerly BB-301) for treating oculopharyngeal muscular dystrophy (OPMD).